首页> 美国卫生研究院文献>Oncology Research >Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients
【2h】

Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients

机译:结直肠癌患者对欧沙拉汀的过敏反应的临床分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study investigated the characteristics of oxaliplatin-induced hypersensitivity reactions (HSRs) and evaluated the efficacy of premedication for controlling HSRs among colorectal cancer patients. A retrospective study was performed on the clinical records of 291 patients with colorectal cancer in The Tenth People’s Hospital of Shanghai from January 2008 to January 2016. Patients who experienced HSRs to oxaliplatin were compared with those who did not. A total of 291 colorectal cancer patients received oxaliplatin, with 39 (13.40%) experiencing HSRs. Oxaliplatin-free interval and premedication with dexamethasone and antihistamine were independent variables for oxaliplatin-related HSRs. Rechallenging patients with premedication was successful in 72.2% of the patients who successfully completed their treatment. Attention should be paid to patients with any prior exposure to oxaliplatin. Patients with grades 1 and 2 HSRs can successfully rechallenge with oxaliplatin and complete their treatment by premedication with dexamethasone and antihistamine.
机译:本研究研究了奥沙利铂诱导的超敏反应(HSRS)的特征,并评估了对结直肠癌患者的HSRS控制HSR的疗效。从2008年1月到2016年1月到2016年1月的上海十分高分癌症患者的临床记录进行了回顾性研究。与那些没有的人比较了奥沙利铂的患者。总共291名结肠直肠癌患者接受奥沙利铂,其中经历了39(13.40%)的HSR。奥沙利铂的间隔和具有地塞米松和抗组胺药的预先思考是奥沙利铂相关的HSR的独立变量。重组患有预测的患者成功完成治疗的72.2%。应注意患者对奥沙利铂发生任何接触的患者。患者1和2 HSRS的患者可以成功地用奥沙利铂再次重新检查,并通过用地塞米松和抗组胺药进行预先进行治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号